Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Reyderman · SciRah

Researcher profile · Semantic Scholar

L. Reyderman

Share profile

L. Reyderman — researcher profile on SciRah

h-index: 13
Works: 30
Citations: 405

Most-cited papers

First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers
D. Hong, A. Parikh, G. Shapiro, A. Varga +16 more
2020Journal for ImmunoTherapy of Cancer56 citations Open access
Semantic Scholar
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment
L. Devriese, P. Witteveen, S. Marchetti, M. Mergui-Roelvink +7 more
2012Cancer Chemotherapy and Pharmacology43 citations
Semantic Scholar
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole
L. Devriese, M. Mergui-Roelvink, J. Wanders, A. Jenner +7 more
2013Investigational new drugs34 citations
Semantic Scholar
Mass Balance Study of [14C]Eribulin in Patients with Advanced Solid Tumors
A. C. Dubbelman, H. Rosing, R. Jansen, M. Mergui-Roelvink +7 more
2012Drug Metabolism And Disposition29 citations
Semantic Scholar
A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors
B. M. Kerklaan, S. Slater, M. Flynn, A. Greystoke +12 more
2016Investigational new drugs28 citations Open access
Semantic Scholar
Eribulin mesylate pharmacokinetics in patients with hepatic impairment.
P. Witteveen, S. Marchetti, M. Mergui-Roelvink, L. Reyderman +6 more
201027 citations
Semantic Scholar
Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
A. Tan, J. Sarantopoulos, Lucy Lee, L. Reyderman +3 more
2014Cancer Chemotherapy and Pharmacology23 citations Open access
Semantic Scholar
Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
O. Majid, Anubha Gupta, L. Reyderman, M. Olivo +1 more
2014Journal of clinical pharmacology21 citations
Semantic Scholar
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors
T. Lesimple, J. Edeline, T. Carrothers, F. Cvitkovic +9 more
2013Investigational new drugs19 citations
Semantic Scholar
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin
L. Devriese, P. Witteveen, J. Wanders, K. Law +9 more
2013British Journal of Clinical Pharmacology19 citations Open access
Semantic Scholar
Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study
R. Tibes, M. Borad, C. Dutcus, L. Reyderman +4 more
2018British Journal of Cancer18 citations Open access
Semantic Scholar
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours
T. Jeffry Evans, E. Dean, L. Molife, Juanita Lopez +10 more
2019British Journal of Cancer16 citations Open access
Semantic Scholar
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314)
E. Schafer, R. Rau, S. Berg, Xiao-Wei Liu +10 more
2018Pediatric Blood & Cancer16 citations Open access
Semantic Scholar
Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer.
T. Mok, Sarayut Lucien Geater, N. Iannotti, S. Thongprasert +10 more
2014Annals of Oncology13 citations Open access
Semantic Scholar
Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors.
M. Borad, C. Akerele, R. Ramanathan, D. Northfelt +5 more
201010 citations
Semantic Scholar
A phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer.
M. Nasim, R. Plummer, T. R. Jeffry Evans, R. Morrison +10 more
20128 citations
Semantic Scholar
A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
C. Twelves, A. Anthoney, C. Savulsky, M. Guo +8 more
2019British Journal of Cancer6 citations Open access
Semantic Scholar
574 Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET)
L. Deviese, J. Wanders, A. Jenner, G. Edwards +6 more
20106 citations
Semantic Scholar
Eribulin dosing in patients with advanced solid tumors and hepatic impairment.
L. Devriese, P. Witteveen, E. E. Voest, E. Overkleeft +8 more
2011Journal of Clinical Oncology4 citations
Semantic Scholar
A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer
S. Goel, U. Swami, Kirushna Kumar, C. Dittrich +5 more
2019Cancer Chemotherapy and Pharmacology3 citations
Semantic Scholar
Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.
D. Hong, A. Parikh, G. Shapiro, A. Varga +15 more
20182 citations
Semantic Scholar
4OPhase 1 study of E7046, a PGE2 receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment (TME)
D. Hong, A. Varga, A. Parikh, G. Shapiro +7 more
20171 citations Open access
Semantic Scholar
Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors
Ishtiaq Zubairi, E. Dean, L. Molife, Juanita Lopez +12 more
20161 citations
Semantic Scholar
Pharmacokinetics of eribulin mesilate in combination with capecitabine in patients with advanced/metastatic cancer: Results from a phase IB dose-escalation study
C. Twelves, M. Nasim, A. Anthoney, N. Cresti +6 more
20121 citations Open access
Semantic Scholar
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children's Oncology Group Phase 1 Consortium study (ADVL1314).
E. Schafer, R. Rau, Xiao-Wei Liu, C. Minard +7 more
20160 citations
Semantic Scholar
599 Effect of Food On Relative Bioavailability of E7820 in Cancer Patients
S. Slater, P. Witteveen, R. Plummer, R. Kristeleit +6 more
20120 citations
Semantic Scholar
Abstract B193: Analysis of the concentration-QTc relationship for eribulin mesylate.
L. Reyderman, T. Carrothers, B. Darpo, A. Kristensen
20110 citations
Semantic Scholar
Eribulin Mesylate Pharmacokinetics in Patients With Advanced Solid Tumours Receiving Rifampicin
L. Devriese, P. Witteveen, S. Marchetti, L. Reyderman +6 more
20110 citations
Semantic Scholar
1244 POSTER An Open-Label, Multicenter, Single Arm QT Interval Prolongation Study of Eribulin Mesylate in Patients With Advanced Solid Tumours
J. Edeline, H. Léna, E. Cvitkovic, N. Penel +5 more
20110 citations
Semantic Scholar
Abstract 1294: Metabolism and excretion of eribulin in patients with advanced solid tumors
A. C. Dubbelman, M. Mergui-Roelvink, B. Koetz, M. Lymboura +6 more
20110 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Wanders×9
Invite
J. Wanders — researcher profile on SciRah
G. Edwards×8
Invite
G. Edwards — researcher profile on SciRah
P. Witteveen×7
Invite
P. Witteveen — researcher profile on SciRah
S. Marchetti×7
Invite
S. Marchetti — researcher profile on SciRah

×7

Invite

J. Beijnen — researcher profile on SciRah

Invite

L. Devriese — researcher profile on SciRah

J. Schellens×5

Invite

J. Schellens — researcher profile on SciRah

Invite

R. Plummer — researcher profile on SciRah

Invite

C. Savulsky — researcher profile on SciRah

Invite

A. Jenner — researcher profile on SciRah

Invite

K. Law — researcher profile on SciRah

Invite

D. Hong — researcher profile on SciRah